MedWatch

Sanofi defeats Novo Nordisk in Danish high court

A press release from Novo Nordisk, comparing Novo's Tresiba to French Sanofi's insulins, was misleading, against the Medicines Act and a violation of good marketing practice. This is the judgment of the Danish Maritime and Commercial High Court.

Foto: /Ritzau Scanpix/Linda Kastrup

In a marketing dispute between Sanofi and Novo Nordisk, the Danish Maritime and Commercial High Court ruled in favor of Novo Nordisk's French rival.

According to the court's judgment, Novo Nordisk acted against the Medicines Act and good marketing conduct when the Danish drug group issued a press release that compared the long-acting insulin Tresiba to Sanofi's insulin products.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier